As part of its Expand and Invest to Grow-strategy, Lundbeck plans to make changes to its organization in Research & Development (R&D).
The initiative could lead to a reduction of around 130-160 positions globally (subject to consultation), including approximately 100 in Denmark.
“The proposed changes will allow us to fully execute on our strategy in the years to come and rebuild our pipeline with innovative programs with strong potential to deliver highly impactful treatments for patients with brain disorders. Through this we will support Lundbeck in becoming the premier neuroscience company, globally,” says Johan Luthman, Executive Vice President, R&D at Lundbeck.
R&D efforts where the science is most promising
The company plans to optimize its R&D-organization to enhance the company’s ability to strengthen and advance its pipeline across all phases in an evolving neuroscience landscape, it states. The plan follows Lundbeck’s Expand and Invest to Grow-strategy of expanding the company’s operating space and rebuilding its pipeline of potential new medicines to treat brain disorders.
Key elements include focusing Lundbeck’s R&D efforts where the science is most promising and on biological platforms were Lundbeck can have world class expertise. Lundbeck will also strengthen competencies to leverage new technologies and will build agility and flexibility into its ways of working in order to lead in the ever-evolving neuroscience landscape.
Lundbeck has informed the company’s Works Council and its European Works Council about the restructuring plans.